Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Filings indexed 4,405 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country FR France
Listing PA SAN

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Avril 2026
Regulatory Filings Classification · 82% confidence The document is a regulatory announcement disclosing Sanofi’s total number of shares and voting rights under French commercial code and AMF regulations. It does not present meeting results, vote outcomes, or constitute a financial report; rather it is a compliance filing. No specific category matches exactly, so it falls under the fallback “Regulatory Filings” (RNS).
2026-05-19 French
Sanofi: Information concerning the total number of voting rights and shares - April 2026
Regulatory Filings Classification · 82% confidence The document is a statutory announcement under French Commercial Code and AMF rules providing the total number of shares and voting rights as of a certain date. It is neither a full financial report nor a vote result, nor a threshold‐crossing shareholding notice. It is a regulatory disclosure of share and voting‐rights structure, thus best classified as a general regulatory filing (RNS).
2026-05-19 English
Communiqué de presse : ATS : Les données de phase 2 démontrent la supériorité de l'efdoralprin alfa par rapport au traitement de substitution standard pour atteindre des taux de fAAT plus élevés dans
Regulatory Filings
2026-05-18 French
Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
Regulatory Filings
2026-05-18 English
6-K - Sanofi (0001121404) (Filer)
Foreign Filer Report
2026-05-05 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 90% confidence The document is titled “Déclaration des transactions sur actions propres” by Sanofi, detailing share repurchase transactions on its own shares over specific dates. This matches the definition for Transaction in Own Shares (Code: POS).
2026-04-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.